ALUMIS INC (ALMS) Stock News
NASDAQ:ALMS - Nasdaq - US0223071020 - Common Stock - Currency: USD
ALMS Latest News and Analysis
What's going on in today's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders
Alumis Strengthens Leadership Team with Key Appointments
Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company....
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs....
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis...
Alumis to Participate in Upcoming September Investor Conferences
Alumis to Participate in Upcoming September Investor Conferences
Alumis will be participating in several investor conferences in September...
ALMS Stock Earnings: Alumis Reported Results for Q2 2024
Alumis just reported results for the second quarter of 2024.
ALMS Stock Earnings: Alumis Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alumis (NASDAQ:ALMS) just reported results for the second quarter of 2024.Alumi...
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis....
Biopharma Firm Alumis Shares Fall 20% After Downsized IPO
Shares of Alumis Inc. sank 20% in the clinical stage biopharmaceutical company’s public debut, after it raised $250 million in a downsized initial public offering with a concurrent private placement.
Alumis Raises $250 Million in Downsized IPO, Private Placement
Alumis Inc., a clinical stage biopharmaceutical company, raised $250 million in a downsized initial public offering with a concurrent private placement, pricing its shares at the bottom of a marketed range.
Alumis Announces Pricing of Initial Public Offering
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering...